Abstract: Objective To analyze the risks of Ginkgo Biloba tablets and other oral preparations, and to provide reference for safe clinical use. Methods The adverse reactions/events reported by China adverse drug reaction monitoring systems and by domestic and foreign literature, as well as risk management measures taken by drug regulatory authorities were analyzed. Results Adverse reactions/events involving multiple systems / organs might occur in clinical use of Ginkgo Biloba tablets and other oral preparations. There was the risk of drug interactions in combination therapies, and there were also some risks to the control of free quercetin, kaempferol and isorhamnetin in the course of production. Conclusion In order to prevent and control the safety risks posed by Ginkgo Biloba tablets and other oral preparations in clinical use, hospitals should strive to ensure clinical rational drug use, marketing authorization holders should fulfill their main responsibility of pharmacovigilance, and institutions of monitoring and evaluation of adverse drug reactions should strengthen the monitoring of adverse reactions.

Key words: Ginkgo Biloba tablets, oral preparations, adverse drug reactions, literature analysis, regulatory measures